We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical vs Boston Scientific: Which Stock Is the Better Buy Post Q1?
Read MoreHide Full Article
Key Takeaways
Intuitive Surgical posted 23% revenue growth and 17% procedure growth, driven by strong global adoption.
Intuitive Surgical raised its full-year procedure growth outlook to 13.5-15.5% on demand strength.
Boston Scientific cut growth guidance amid headwinds like slowing WATCHMAN demand and margin pressures.
Both Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) delivered solid first-quarter 2026 results, but the quality and trajectory of growth diverged meaningfully.
ISRG reported revenues of $2.77 billion, up 23% year over year, with EPS of $2.50, reflecting strong operating leverage and continued procedure growth. BSX generated revenues of $5.20 billion, up 11.6%, with EPS of $0.80, supported by steady performance across its key franchises. While Intuitive Surgical’s sales and EPS exceeded estimates by 6.2% and 20.2%, respectively, Boston Scientific’s revenues were in line with expectations and EPS beat estimates by 0.4%.
ISRG stock has risen 6.1% since release, while BSX has improved 1.3%. Looking ahead, Intuitive Surgical appears well-positioned for sustained high-teens growth, whereas Boston Scientific faces a more moderate outlook amid emerging headwinds.
Price Performance
So far this year, Intuitive Surgical has declined 15.5% compared with Boston Scientific’s plunge of 31.1%. While the broader Medical sector was down 6.6%, the S&P 500 Index gained 4.4% in the same period.
YTD Price Chart ISRG vs BSX
Image Source: Zacks Investment Research
Case for ISRG
Intuitive Surgical’s first-quarter performance underscores the strength of its procedure-driven model and innovation-led growth strategy. Total procedures grew 17%, including 16% growth in da Vinci and 39% growth in Ion, reflecting broad-based adoption globally. Revenue growth of 23% outpaced procedure growth, driven by higher system placements, increased utilization of the da Vinci 5 platform, and pricing benefits tied to innovation.
The company’s recurring revenue base remains a key earnings driver, with instruments and accessories accounting for 86% of total revenues, reinforcing visibility and margin expansion. Margin performance was robust, with operating margin reaching 39%, highlighting strong cost leverage.
ISRG raised its full-year procedure growth outlook to 13.5-15.5%, signaling confidence in continued demand and platform adoption. Growth is expected to be driven by general surgery expansion in the United States, international penetration, and continued rollout of advanced capabilities, such as Force Feedback and AI-enabled tools. While challenges persist in China and Japan, ISRG’s expanding installed base and innovation pipeline position it for sustained top-line and earnings momentum through 2026.
ISRG’s Consensus Estimate Movement
Image Source: Zacks Investment Research
Case for BSX
Boston Scientific delivered a solid quarter, with organic revenue increase of 9.4% and EPS growth of 6%, supported by strength in cardiovascular, electrophysiology (EP), and neuromodulation businesses. This growth was driven by products such as FARAPULSE, WATCHMAN, and interventional cardiology therapies, highlighting the company’s diversified portfolio.
However, the outlook has moderated. Management lowered full-year organic growth guidance to 6.5-8% and expects EPS growth of 9-11%, citing unanticipated headwinds and shifting demand patterns. Key challenges include slowing WATCHMAN procedure growth due to changing clinical practices and hospital capacity constraints, increased competition in EP and underperformance in the Urology segment.
Margin pressures from tariffs, product mix, and supply-chain investments are expected to weigh on profitability. While BSX maintains confidence in its long-term growth strategy, near-term execution appears more complex, with the second quarter expected to be the most challenging period of the year.
BSX’s Consensus Estimate Movement
Image Source: Zacks Investment Research
Valuation Comparison
ISRG trades at a premium, but this valuation is supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 46.11, well above the industry average of 26.62, and carries a Value Score of D.
ISRG’s P/E F12M Chart
Image Source: Zacks Investment Research
BSX offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 18.3, above the industry average of 17.44. BSX carries a Value Score of C.
BSX’s P/E F12M Chart
Image Source: Zacks Investment Research
Conclusion
Both Intuitive Surgical and Boston Scientific remain high-quality MedTech players with strong market positions and innovation pipelines. ISRG’s superior growth profile, innovation-led revenue expansion, and raised 2026 outlook provide greater visibility into sustained earnings momentum. In contrast, BSX’s lowered guidance and emerging operational headwinds suggest a more cautious near-term trajectory. With ISRG delivering stronger upside surprises and demonstrating clearer acceleration, it stands out as the better investment choice at present. BSX, on the other hand, appears more appropriately positioned as a hold.
View the Zacks #1 Rank List
Image: Bigstock
Intuitive Surgical vs Boston Scientific: Which Stock Is the Better Buy Post Q1?
Key Takeaways
Both Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) delivered solid first-quarter 2026 results, but the quality and trajectory of growth diverged meaningfully.
ISRG reported revenues of $2.77 billion, up 23% year over year, with EPS of $2.50, reflecting strong operating leverage and continued procedure growth. BSX generated revenues of $5.20 billion, up 11.6%, with EPS of $0.80, supported by steady performance across its key franchises. While Intuitive Surgical’s sales and EPS exceeded estimates by 6.2% and 20.2%, respectively, Boston Scientific’s revenues were in line with expectations and EPS beat estimates by 0.4%.
ISRG stock has risen 6.1% since release, while BSX has improved 1.3%. Looking ahead, Intuitive Surgical appears well-positioned for sustained high-teens growth, whereas Boston Scientific faces a more moderate outlook amid emerging headwinds.
Price Performance
So far this year, Intuitive Surgical has declined 15.5% compared with Boston Scientific’s plunge of 31.1%. While the broader Medical sector was down 6.6%, the S&P 500 Index gained 4.4% in the same period.
YTD Price Chart ISRG vs BSX
Image Source: Zacks Investment Research
Case for ISRG
Intuitive Surgical’s first-quarter performance underscores the strength of its procedure-driven model and innovation-led growth strategy. Total procedures grew 17%, including 16% growth in da Vinci and 39% growth in Ion, reflecting broad-based adoption globally. Revenue growth of 23% outpaced procedure growth, driven by higher system placements, increased utilization of the da Vinci 5 platform, and pricing benefits tied to innovation.
The company’s recurring revenue base remains a key earnings driver, with instruments and accessories accounting for 86% of total revenues, reinforcing visibility and margin expansion. Margin performance was robust, with operating margin reaching 39%, highlighting strong cost leverage.
ISRG raised its full-year procedure growth outlook to 13.5-15.5%, signaling confidence in continued demand and platform adoption. Growth is expected to be driven by general surgery expansion in the United States, international penetration, and continued rollout of advanced capabilities, such as Force Feedback and AI-enabled tools. While challenges persist in China and Japan, ISRG’s expanding installed base and innovation pipeline position it for sustained top-line and earnings momentum through 2026.
ISRG’s Consensus Estimate Movement
Image Source: Zacks Investment Research
Case for BSX
Boston Scientific delivered a solid quarter, with organic revenue increase of 9.4% and EPS growth of 6%, supported by strength in cardiovascular, electrophysiology (EP), and neuromodulation businesses. This growth was driven by products such as FARAPULSE, WATCHMAN, and interventional cardiology therapies, highlighting the company’s diversified portfolio.
However, the outlook has moderated. Management lowered full-year organic growth guidance to 6.5-8% and expects EPS growth of 9-11%, citing unanticipated headwinds and shifting demand patterns. Key challenges include slowing WATCHMAN procedure growth due to changing clinical practices and hospital capacity constraints, increased competition in EP and underperformance in the Urology segment.
Margin pressures from tariffs, product mix, and supply-chain investments are expected to weigh on profitability. While BSX maintains confidence in its long-term growth strategy, near-term execution appears more complex, with the second quarter expected to be the most challenging period of the year.
BSX’s Consensus Estimate Movement
Image Source: Zacks Investment Research
Valuation Comparison
ISRG trades at a premium, but this valuation is supported by sustained double-digit growth, expanding global adoption, and a long runway in minimally invasive surgery. Its performance demonstrates resilience despite external pressures, such as tariffs. The company currently trades at a forward 12-month P/E multiple of 46.11, well above the industry average of 26.62, and carries a Value Score of D.
ISRG’s P/E F12M Chart
Image Source: Zacks Investment Research
BSX offers a more balanced risk profile, with dependable earnings growth and margin expansion driven by operational discipline. Its upside potential appears comparatively constrained, given its mature and diversified business mix. The company currently trades at P/E F12M ratio of 18.3, above the industry average of 17.44. BSX carries a Value Score of C.
BSX’s P/E F12M Chart
Image Source: Zacks Investment Research
Conclusion
Both Intuitive Surgical and Boston Scientific remain high-quality MedTech players with strong market positions and innovation pipelines. ISRG’s superior growth profile, innovation-led revenue expansion, and raised 2026 outlook provide greater visibility into sustained earnings momentum. In contrast, BSX’s lowered guidance and emerging operational headwinds suggest a more cautious near-term trajectory. With ISRG delivering stronger upside surprises and demonstrating clearer acceleration, it stands out as the better investment choice at present. BSX, on the other hand, appears more appropriately positioned as a hold.
While Intuitive Surgical currently carries a Zacks Rank #2 (Buy), Boston Scientific has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.